Advertisement
Research Article Free access | 10.1172/JCI119396
Department of Clinical Viro-Immunology, Laboratory of Experimental and Clinical Immunology of the University of Amsterdam, The Netherlands.
Find articles by Rep, M. in: JCI | PubMed | Google Scholar
Department of Clinical Viro-Immunology, Laboratory of Experimental and Clinical Immunology of the University of Amsterdam, The Netherlands.
Find articles by van Oosten, B. in: JCI | PubMed | Google Scholar
Department of Clinical Viro-Immunology, Laboratory of Experimental and Clinical Immunology of the University of Amsterdam, The Netherlands.
Find articles by Roos, M. in: JCI | PubMed | Google Scholar
Department of Clinical Viro-Immunology, Laboratory of Experimental and Clinical Immunology of the University of Amsterdam, The Netherlands.
Find articles by Adèr, H. in: JCI | PubMed | Google Scholar
Department of Clinical Viro-Immunology, Laboratory of Experimental and Clinical Immunology of the University of Amsterdam, The Netherlands.
Find articles by Polman, C. in: JCI | PubMed | Google Scholar
Department of Clinical Viro-Immunology, Laboratory of Experimental and Clinical Immunology of the University of Amsterdam, The Netherlands.
Find articles by van Lier, R. in: JCI | PubMed | Google Scholar
Published May 1, 1997 - More info
CD4(pos) TH1 T cells are considered to play a central role in a number of human autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis. Experimental treatment protocols aimed at selectively eliminating CD4(pos) T cells thus far have yielded disappointing clinical results. Here we analyzed phenotype and function of circulating T cells in multiple sclerosis patients treated with the chimeric CD4 mAb cM-T412 in a randomized, double-blind, placebo-controlled, magnetic resonance imaging-monitored phase II trial. Treatment resulted in a long-lasting depletion of CD4(pos) T cells but did not affect CD8(pos) T cell numbers. Analysis of CD4(pos) subpopulations showed that unprimed, CD45RA(pos)/R0(neg) lymphocytes were approximately three times more sensitive to the mAb than primed, CD45RA(neg)/R0(pos) T cells. Notably, within the CD45RA(pos) subset, T cells with phenotypic evidence of prior activation, i.e., expressing Fas, were relatively insensitive to cM-T412, compared with Fas(neg) cells. Remarkably, while a decrease in the number of IL-4-producing T helper 2 (TH2)-type cells in the anti-CD4 treated group was observed, numbers of IFN-gamma-producing T helper 1 (TH1)-type cells remained stable, resulting in a significant increase in the TH1/TH2 ratio. Our data show that treatment with depleting CD4 mAb does not eliminate the cells most strongly involved in the disease process, i.e., primed, IFN-gamma-producing TH1-type cells, and may therefore give an explanation for the lack of beneficial clinical effects of depleting CD4 mAb in human chronic autoimmune disease.